Substance / Medication

Ranitidine bismuth citrate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Duodenal ulcer disease

Zollinger-Ellison syndrome

Gastroesophageal reflux disease

Gastric ulcer

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy.

Gisbert J P, González L, Calvet X et al. · Aliment Pharmacol Ther · 2000

PMID: 10971230Meta-Analysis

Pretreatment with Ranitidine Bismuth Citrate May Improve Success Rates of Helicobacter pylori Eradication: A Prospective, Randomized, Controlled and Open-Label Study.

Yoon Jin Young, Kwak Min Seob, Jeon Jung Won et al. · Tohoku J Exp Med · 2021

PMID: 34526429RCT

The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication.

Akyildiz Murat, Akay Sinan, Musoglu Ahmet et al. · Eur J Intern Med · 2009

PMID: 19237093RCT

Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.

Kiliç Zeki Mesut Yalin, Köksal Aydin Seref, Cakal Başak et al. · Dig Dis Sci · 2008

PMID: 18465244RCT

7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure.

Gisbert J P, Fuentes J, Carpio D et al. · Aliment Pharmacol Ther · 2005

PMID: 15882246Trial

One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer.

Mesquita Maria Aparecida, Lorena Sonia Letícia Silva, Almeida Jazon Romilson Souza et al. · World J Gastroenterol · 2005

PMID: 15962376TrialFull text (PMC)

Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.

Köksal Aydin S, Parlak Erkan, Filik Levent et al. · J Gastroenterol Hepatol · 2005

PMID: 15836716Trial

Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.

Altintaş Engin, Ulu Oğuz, Sezgin Orhan et al. · Turk J Gastroenterol · 2004

PMID: 15334317Trial

A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori.

Veldhuyzen van Zanten Sander, Chiba Naoki, Barkun Alan et al. · Can J Gastroenterol · 2003

PMID: 14532926Trial

Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.

Farup P G, Tholfsen J, Wetternus S et al. · Scand J Gastroenterol · 2002

PMID: 12523585Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Ranitidine bismuth citrate (substance)
SNOMED CT: 386886000
UMLS CUI: C0139919

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.